Dimensional Fund Advisors LP Acquires 238,075 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Dimensional Fund Advisors LP increased its stake in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 15.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,802,364 shares of the company's stock after acquiring an additional 238,075 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.23% of MiMedx Group worth $17,338,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. IMG Wealth Management Inc. purchased a new stake in shares of MiMedx Group in the fourth quarter worth approximately $28,000. Van ECK Associates Corp acquired a new stake in shares of MiMedx Group in the fourth quarter valued at about $40,000. AlphaQuest LLC acquired a new stake in MiMedx Group in the 4th quarter valued at approximately $88,000. Koss Olinger Consulting LLC bought a new position in MiMedx Group during the fourth quarter worth $100,000. Finally, Savant Capital LLC bought a new position in MiMedx Group during the fourth quarter valued at about $100,000. Hedge funds and other institutional investors own 79.15% of the company's stock.

MiMedx Group Price Performance

Shares of MDXG stock traded down $0.30 on Friday, hitting $7.12. 1,111,673 shares of the company's stock were exchanged, compared to its average volume of 695,443. The company has a 50 day moving average of $7.28 and a 200 day moving average of $8.13. The stock has a market cap of $1.05 billion, a P/E ratio of 12.95 and a beta of 1.85. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The company had revenue of $88.21 million during the quarter, compared to analyst estimates of $86.32 million. On average, equities research analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Analysts Set New Price Targets

MDXG has been the topic of a number of recent analyst reports. StockNews.com lowered shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a report on Thursday, February 27th.

Insider Buying and Selling at MiMedx Group

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 4,106 shares of the firm's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the sale, the insider now owns 310,836 shares of the company's stock, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO William Frank Iv Hulse sold 54,596 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $430,762.44. Following the transaction, the chief accounting officer now directly owns 440,178 shares in the company, valued at $3,473,004.42. This trade represents a 11.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 144,018 shares of company stock worth $1,130,312 over the last three months. 1.30% of the stock is currently owned by insiders.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.